Skip to main content
Fig. 8 | Biomarker Research

Fig. 8

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Fig. 8

Growth inhibition of malignant tumor cells and PBMCs from the same patients with oncogene-driven NSCLC by TKIs and ICIs. Tumor cells isolated from malignant pleural effusion and PBMCs isolated from the peripheral blood of individual patients were cocultured for 12 h before treated with specific TKI and/or ICIs. H1975 cells (A) and osimertinib-resistant NSCLC cells (B) were cultured with patient’s PBMCs, and treated with vehicle, osimertinib (0.1 μM), nivolumab (10 μg/ml), atezolizumab (10 μg/ml) or combination as indicated for 72 h. Growth inhibition was measured using the MTS assay using vehicle as 100% control. Alectinib-sensitive ALK-fusion NSCLC cells (C) and alectinib-resistant RET-fusion NSCLC cells (D) were cocultured with PBMCs from corresponding patients and treated with vehicle, alectinib (0.1 μM), nivolumab (10 μg/ml), atezolizumab (10 μg/ml) or combination as indicated for 72 h. Growth inhibition was measured using the MTS assay with vehicle as 100% control. All data are shown as mean of triplicate samples. Error bars indicate standard deviation (SD). Groups were compared by the Wilcoxon signed rank test. P < 0.05 was considered statistically significant. Abbreviations: MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)

Back to article page